Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System.

artificial pancreas closed-loop hypoglycaemia type 1 diabetes

Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
29 Sep 2022
Historique:
entrez: 29 9 2022
pubmed: 30 9 2022
medline: 30 9 2022
Statut: aheadofprint

Résumé

Automated insulin delivery is an efficient treatment for patients with type 1 diabetes. Little is known on its impact on patients with excessive time in hypoglycaemia. We performed a post hoc analysis of three randomized control trials that used the DBLG1 (Diabeloop Generation 1) hybrid closed-loop solution. Patients whose time below 70 mg/dL during baseline, open-loop phase exceeded 5% were selected. The outcomes were the differences between the closed-loop and the open-loop phases in time in various ranges and Glycemia Risk Index (GRI). We identified 45 patients exhibiting ≥5% of time below 70 mg/dL during the open-loop phase. Under closed-loop, the time in hypoglycaemia (54 to <70 mg/dL) dropped from 7.9% (SD 2.4) to 3.2% (SD 1.6) (difference -4.7% [-5.3; -4.1], DBLG1 decreased time in hypoglycaemia by more than 50% even in patients with excessive time in hypoglycaemia at baseline, while also improving both TIR and GRI, under real-life conditions. The improvement in GRI (13.2%) exceeded that of the improvement in TIR (5.1%) indicating that in this data set, GRI was more sensitive than TIR to the improvement in glycaemia achieved with closed-loop. These results support the safety and efficacy of this treatment.

Sections du résumé

BACKGROUND UNASSIGNED
Automated insulin delivery is an efficient treatment for patients with type 1 diabetes. Little is known on its impact on patients with excessive time in hypoglycaemia.
METHODS UNASSIGNED
We performed a post hoc analysis of three randomized control trials that used the DBLG1 (Diabeloop Generation 1) hybrid closed-loop solution. Patients whose time below 70 mg/dL during baseline, open-loop phase exceeded 5% were selected. The outcomes were the differences between the closed-loop and the open-loop phases in time in various ranges and Glycemia Risk Index (GRI).
RESULTS UNASSIGNED
We identified 45 patients exhibiting ≥5% of time below 70 mg/dL during the open-loop phase. Under closed-loop, the time in hypoglycaemia (54 to <70 mg/dL) dropped from 7.9% (SD 2.4) to 3.2% (SD 1.6) (difference -4.7% [-5.3; -4.1],
CONCLUSION UNASSIGNED
DBLG1 decreased time in hypoglycaemia by more than 50% even in patients with excessive time in hypoglycaemia at baseline, while also improving both TIR and GRI, under real-life conditions. The improvement in GRI (13.2%) exceeded that of the improvement in TIR (5.1%) indicating that in this data set, GRI was more sensitive than TIR to the improvement in glycaemia achieved with closed-loop. These results support the safety and efficacy of this treatment.

Identifiants

pubmed: 36172702
doi: 10.1177/19322968221128565
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19322968221128565

Auteurs

Pierre-Yves Benhamou (PY)

Department of Endocrinology, Grenoble University Hospita, INSERM U1055, Laboratory of Fundamental and Applied Bioenergetics, Grenoble Alpes University, Grenoble, France.
Department of Endocrinology, Univ. Grenoble Alpes, Centre Hospitalier Universitaire Grenoble Alpes.

Alice Adenis (A)

Diabeloop SA, Paris, France.

Yousra Tourki (Y)

Diabeloop SA, Paris, France.

Sylvie Pou (S)

Diabeloop SA, Paris, France.

Stéphanie Madrolle (S)

Diabeloop SA, Paris, France.

Sylvia Franc (S)

Center for Study and Research for Improvement of the Treatment of Diabetes, Bioparc-Genopole Evry-Corbeil, Evry, France.
Department of Diabetes and Endocrinology, Sud-Francilien Hospital, Corbeil, France.

Dulanjalee Kariyawasam (D)

Department of Paediatric Endocrinology, Diabetology and Gynaecology, Necker-Enfants Malades University Hospital, Assistance Publique des Hôpitaux de Paris-Centre, Paris, France.
Paris Cite University, Paris, France.

Jacques Beltrand (J)

Department of Paediatric Endocrinology, Diabetology and Gynaecology, Necker-Enfants Malades University Hospital, Assistance Publique des Hôpitaux de Paris-Centre, Paris, France.
Paris Cite University, Paris, France.

David C Klonoff (DC)

Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA.

Guillaume Charpentier (G)

Center for Study and Research for Improvement of the Treatment of Diabetes, Bioparc-Genopole Evry-Corbeil, Evry, France.
Department of Diabetes and Endocrinology, Sud-Francilien Hospital, Corbeil, France.

Classifications MeSH